From May 15th to 17th, 2017, the 77th National Pharmaceutical Fair was grandly held at the Shanghai National Convention and Exhibition Center. This is the largest and most influential industry event in China's pharmaceutical industry. 2,000 pharmaceutical companies participated in the exhibition, and 70% of the top 100 domestic pharmaceutical companies set up booths. The high industry participation attracted 120,000 professional visitors from more than 30 provinces, cities and regions across the country.
In this trade fair, Yang Bo, general manager of Shenyang Hongqi Pharmaceutical Co., Ltd. (hereinafter referred to as Hongqi Pharmaceutical), led the company's operations, commerce, sales, and supply departments to participate in the fair, as well as the heads of many participating manufacturers of raw materials, preparations, and imported products , Imported product agents conducted a number of compact meetings and negotiations. During the meeting, General Manager Yang Bo gave a detailed introduction to the future development plan of Hongqi Pharmaceutical and the construction of the National Supply Coordination Reserve in cooperation with the China National Tuberculosis Association, including the progress of enriching the company's product line, the Double Thousand Action, and the Chinese Medical Association. For the cooperative young eagle plan, many participating manufacturers expressed their willingness to cooperate with Hongqi Pharmaceutical.
Through this trade fair, Hongqi Pharmaceutical has established a closer business relationship with related manufacturers and implemented multiple cooperation intentions, demonstrating Hongqi Pharmaceutical’s confidence and determination to become a world-class anti-tuberculosis drug pharmaceutical company, and contributing to the future development of Hongqi Pharmaceutical Lay a solid foundation.
(As the country’s largest R&D and production base of anti-tuberculosis drugs, Hongqi Pharmaceutical has made important contributions to the defense of tuberculosis in China. At present, its first-line anti-tuberculosis drugs are Rifampicin Capsules, Rifampicin Capsules II, Isoniazid Tablets, and B Butterol tablets (capsules), pyrazinamide tablets (capsules), prothionamide enteric-coated tablets, etc., have always been in the forefront of domestic sales. In particular, FDC (fixed-dose compound) products have two daily and alternate daily doses. Drugs. At present, Hongqi Pharmaceutical’s anti-tuberculosis drugs have been serialized. Under the background of China's establishment and improvement of a new type of tuberculosis prevention and control system, Hongqi Pharmaceutical will innovate more good products and make greater contributions to the cause of China’s tuberculosis defense. )
